Advanced Solid Tumors Clinical Trials in Houston, Texas

34 studies are recruiting for advanced solid tumors in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

3. A Study of BG-C477 in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   59 in total

   Run by

   BeOne Medicines

   See if you can join NCT06596473 on ClinicalTrials.gov

4. A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

   Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main g…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology ( Site 1011), Houston, Texas

   Locations

   49 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06818643 on ClinicalTrials.gov

5. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

6. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

   Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how wel…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas

   Locations

   54 in total

   Run by

   Bayer

   See if you can join NCT06760819 on ClinicalTrials.gov

7. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

   The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas - M.D. Anderson Cancer Center, Houston, Texas

   Locations

   22 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT06795412 on ClinicalTrials.gov

8. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

9. Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

   The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   8 in total

   Run by

   Gilead Sciences

   See if you can join NCT06167317 on ClinicalTrials.gov

10. Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

    This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas - MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06384352 on ClinicalTrials.gov

11. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

12. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

    This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas, MD Anderson Cancer Center, Houston, Texas

    Locations

    19 in total

    Run by

    Marengo Therapeutics, Inc.

    See if you can join NCT05592626 on ClinicalTrials.gov

13. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, Houston, Texas

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

14. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    9 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07397338 on ClinicalTrials.gov

15. A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

    This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    16 in total

    Run by

    Sun Pharma Advanced Research Company Limited

    See if you can join NCT07042100 on ClinicalTrials.gov

16. A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

    This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT07460375 on ClinicalTrials.gov

17. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

18. A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

    The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    11 in total

    Run by

    Amgen

    See if you can join NCT07172919 on ClinicalTrials.gov

19. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    15 in total

    Run by

    Ensem Therapeutics

    See if you can join NCT06993844 on ClinicalTrials.gov

20. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Houston, Texas

    Locations

    12 in total

    Run by

    Alterome Therapeutics, Inc.

    See if you can join NCT06835569 on ClinicalTrials.gov

21. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas, MD Anderson Cancer Center, Houston, Texas

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

22. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

    A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

    Stage

    Phase 1

    Ages

    16 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    6 in total

    Run by

    SEED Therapeutics, Inc.

    See if you can join NCT07197554 on ClinicalTrials.gov

23. A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

    The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    28 in total

    Run by

    Jiangsu HengRui Medicine Co., Ltd.

    See if you can join NCT05277168 on ClinicalTrials.gov

24. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

25. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MDACC, Houston, Texas

    Locations

    26 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT05954312 on ClinicalTrials.gov